Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Pandion Therapeutics, Inc. (PAND)
|
|
| Income Statement |
|
|
|
| Standardized | As Reported |
Annual | Quarterly | TTM |
|
| In millions, except per share items | Dec-31-20 | Sep-30-20 | Jun-30-20 | Mar-31-20 | Dec-31-19 | Sep-30-19 | Jun-30-19 | Mar-31-19 |
| | 10-K | 10-Q | 10-Q | S-1/A | 10-K | 10-Q | 10-Q | S-1/A |
| Revenues | 2.2 | 2.6 | 2.0 | 1.0 | 1.0 | 0.0 | 0.0 | 8.4 |
| Revenue growth | 126.6% | | | -88.5% | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 23.2 | 0.0 | 0.0 | 0.0 | 11.0 |
| Gross profit | 2.2 | 2.6 | 2.0 | -22.2 | 1.0 | 0.0 | 0.0 | -2.7 |
| Gross margin | 100.0% | 100.0% | 100.0% | -2297.7% | 100.0% | | | -31.7% |
| Selling, general and administrative [+] | 4.6 | 4.3 | 2.3 | 5.0 | 1.9 | 1.5 | 0.8 | 2.7 |
| General and administrative | 4.6 | 4.3 | 2.3 | 5.0 | 1.9 | 1.5 | 0.8 | 2.7 |
| Research and development | 8.8 | 9.3 | 8.9 | | 3.8 | 4.4 | 4.9 | |
| Other operating expenses | | | | -5.0 | | | | 5.7 |
| EBITDA [+] | -11.0 | -10.8 | -9.0 | | -4.6 | -5.8 | -5.7 | |
| EBITDA growth | 139.5% | 85.4% | 59.5% | 101.1% | | | | |
| EBITDA margin | -504.2% | -411.6% | -461.9% | -2297.7% | -477.0% | | | -131.7% |
| Depreciation and amortization | 0.2 | 0.2 | 0.2 | | 0.1 | 0.1 | 0.1 | |
| EBIT [+] | -11.2 | -11.0 | -9.2 | -22.2 | -4.7 | -5.9 | -5.8 | -11.0 |
| EBIT growth | 140.0% | 86.0% | 59.4% | 101.1% | | | | |
| EBIT margin | -512.5% | -417.6% | -470.7% | -2297.7% | -483.8% | | | -131.7% |
| Interest income, net [+] | 0.0 | -0.2 | 0.0 | 0.2 | 0.0 | 0.1 | 0.1 | 0.2 |
| Interest expense | 0.0 | 0.3 | 0.0 | 0.0 | 0.0 | | | 0.0 |
| Interest income | 0.0 | 0.0 | 0.0 | 0.3 | 0.1 | 0.1 | 0.1 | 0.2 |
| Other income (expense), net | | | | 0.1 | 0.1 | | | |
| Pre-tax income | -11.2 | -11.2 | -9.2 | -21.9 | -4.5 | -5.8 | -5.7 | -10.9 |
| Income taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net income | -11.2 | -11.9 | -11.9 | 0.0 | -5.6 | -6.9 | -6.7 | 0.0 |
| Net margin | -511.9% | -452.0% | -611.2% | -2.7% | -574.5% | | | -0.2% |
| |
| Basic EPS [+] | ($0.83) | ($0.51) | ($10.15) | ($25.00) | ($5.37) | ($6.72) | ($6.30) | ($17.00) |
| Growth | -84.6% | -92.4% | 61.0% | 47.0% | | | | |
| Diluted EPS [+] | ($0.83) | ($0.51) | ($10.15) | ($25.00) | ($5.37) | ($6.72) | ($6.30) | ($17.00) |
| Growth | -84.6% | -92.4% | 61.0% | 47.0% | | | | |
| |
| Shares outstanding (basic) [+] | 13.6 | 23.3 | 1.2 | 0.0 | 1.0 | 1.0 | 1.1 | 0.0 |
| Growth | 1210.4% | 2176.4% | 11.3% | 33.0% | | | | |
| Shares outstanding (diluted) [+] | 13.6 | 23.3 | 1.2 | 0.0 | 1.0 | 1.0 | 1.1 | 0.0 |
| Growth | 1210.4% | 2176.4% | 11.3% | 33.0% | | | | |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|